
February 21, 2023
Nirvana Life Sciences Inc., (CSE:NIRV) ("Nirvana" or the "Company") a Canadian based life sciences company aimed at developing non-addictive chronic pain and addiction treatment products announces that Mr. Chris Hoffmeister has resigned from the Company's Board of Directors. The Company thanks Mr. Hoffmeister for his service over the last 4 years.
About Nirvana Life Sciences
Nirvana Life Sciences Inc. (CSE:NIRV) is an innovator in the emerging Psychedelic space. At Nirvana, we believe that psylocibin derived medicines can play a leading role in reducing the impacts of the opioids crisis and build healthier communities.
For more information visit https://nirvanalifescience.com/
For further information: Bruce Clark, CEO info@nirvanalifescience.com Phone: 604-401-8100
The Canadian Securities Exchange has neither approved nor disapproved the contents of this news release and accepts no responsibility for the adequacy or accuracy hereof.
NIRV:CC
The Conversation (0)
07 April 2022
Nirvana Life Sciences
Psychedelics for Opioid Addiction Recovery and Pain Management
Psychedelics for Opioid Addiction Recovery and Pain Management Keep Reading...
06 July 2022
Nirvana Life Sciences Inc. Announces License for a Delivery System for Psychedelic APIs
Nirvana Life Sciences Inc. (Nirvana or the "Company") (CSE: NIRV), a western Canadian based life sciences company aimed at developing psychedelic therapeutic medicines, including non-addictive chronic pain and relapse preventing products is pleased to announce it has acquired an exclusive... Keep Reading...
28 June 2022
Nirvana Life Sciences Announces Approval To Build Vancouver Facility From Health Canada
Nirvana Life Sciences Inc. (Nirvana or the "Company") (CSE: NIRV), a western Canadian based life sciences company aimed at developing non-addictive chronic pain and relapse preventing products is pleased to announce that Health Canada has given Nirvana an approval to build out its Research &... Keep Reading...
23 June 2022
Nirvana Life Sciences announces filing of Patent for novel isolation of 4-PO-Psilocin Prodrug Compound
Nirvana Life Sciences Inc. (Nirvana or the "Company") (CSE: NIRV) a western Canadian based life sciences company aimed at developing non-addictive chronic pain and relapse preventing products is pleased to report that it has filed a provisional patent application for a novel process for the... Keep Reading...
09 June 2022
Nirvana Life Sciences Announces Patent Filing
The Patent Application contains new inventive claims for extraction as well as inventive methods for use of Psilocybin to affect relapse. Nirvana Life Sciences Inc. (Nirvana or the "Company") (CSE: NIRV), a Canadian based life sciences company focused on developing novel therapeutic products... Keep Reading...
02 June 2022
Nirvana Life Sciences Announces Positive Results for Addiction Relapse Prevention from Their Latest Pre-Clinical Psychedelic Drug Study
Psilocybin reduced reinstatement of heroin-seeking behavior when administered immediately after a memory retrieval task in ratsNirvana Life Sciences Inc. (CSE: NIRV) (Nirvana or the "Company"), a Canadian-based life sciences company focused on developing novel therapeutic products derived from... Keep Reading...
10 October
Numinus Wellness Announces Change of Auditor
Numinus Wellness Inc. (TSX: NUMI) (OTCQB: NUMIF) ("Numinus" or the "Company"), a mental health care company focused on innovative behavioral health treatments with a focus on safe, evidence-based psychedelic-assisted therapies, announces that Davidson & Company LLP ("Davidson") has resigned as... Keep Reading...
16 September
Lobe Sciences Ltd. to Attend the ArcStone-Kingswood Growth Summit 2025 in Toronto
lobe sciences ltd. (CSE: LOBE,OTC:LOBEF) (OTCQB: LOBEF) (FSE: LOBE.F) ("Lobe Sciences" or the "Company") a clinical stage biopharmaceutical company focused on developing products to treat diseases with significant unmet medical needs is pleased to announce its participation in the upcoming... Keep Reading...
30 July
Psychedelics Market Update: H1 2025 in Review
The market for psychedelic drugs is emerging as a strategic investment opportunity in healthcare, with forecasts generally placing its value at around US$6.4 billion in 2025. This burgeoning sector is set for robust, double-digit compound annual growth, significantly driven by North America,... Keep Reading...
08 May
US Policy Momentum, Clinical Progress Fueling Psychedelics Market in 2025
When the US Food and Drug Administration (FDA) rejected Lykos Therapeutics’ new drug application for MDMA-assisted therapy last August, the initial disappointment cast a shadow over the psychedelics industry. However, the sector is seeing a resurgence of optimism in 2025 on the back of various... Keep Reading...
03 March
Avecho and Sandoz enter Exclusive License and Development Agreement to Commercialise CBD for Insomnia in Australia
Avecho Biotechnology Limited (ASX: AVE) (“Avecho” or the “Company”) today announced it has signed an exclusive ten-year development and licensing agreement with Sandoz Group AG (“Sandoz”) for the commercial rights to Avecho’s Phase III cannabidiol (“CBD”) capsule for insomnia in Australia.... Keep Reading...
18 February
Compass Pathways to announce fourth quarter and year-end financial results on February 27th, 2025
Compass management will host a conference call at 8:00 am ET (1:00pm UK) Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, announced today that it will release financial results for the fourth... Keep Reading...
Latest News
Latest Press Releases
Related News
TOP STOCKS
American Battery4.030.24
Aion Therapeutic0.10-0.01
Cybin Corp2.140.00





